Bausch + Lomb Corporation (TSX:BLCO)
| Market Cap | 8.82B +21.4% |
| Revenue (ttm) | 7.56B +8.9% |
| Net Income | -242.84M |
| EPS | -0.68 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 16.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,100 |
| Open | 24.70 |
| Previous Close | 24.37 |
| Day's Range | 24.67 - 24.90 |
| 52-Week Range | 19.36 - 25.70 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during heali... [Read more]
Financial Performance
In 2025, Bausch + Lomb's revenue was $5.10 billion, an increase of 6.47% compared to the previous year's $4.79 billion. Losses were -$360.00 million, 13.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Bausch + Lomb advances oral treatment for dry AMD after FDA meeting
The company states: “Bausch + Lomb (BLCO) announced progress in the development of BL1243, tonabersat, an investigational oral treatment for dry age-related macular degeneration (AMD), following a con...
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in th...
Bausch + Lomb initiated with an Overweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Bausch + Lomb (BLCO) with an Overweight rating and $24 price target The firm rolled out coverage of the medical suppliers and devices…
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter...
Bausch + Lomb announces European CE Mark approval of SeeLyra
Bausch + Lomb (BLCO) announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons...
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Ma...
Leerink bullish on Bausch + Lomb, initiates with an Outperform
As previously reported, Leerink initiated coverage of Bausch + Lomb (BLCO) with an Outperform rating and $24 price target The firm names the stock a Top Pick as current dry…
Bausch + Lomb initiated with an Outperform at Leerink
Leerink initiated coverage of Bausch + Lomb (BLCO) with an Outperform rating and $24 price target
Bausch + Lomb publishes new research on en Vista Aspire IOLs
Bausch + Lomb (BLCO) announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses, or IOLs. The study, published in the…
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publicatio...
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from ...
Bausch + Lomb Transcript: Study result
A novel dual-action dry eye therapy demonstrated rapid, significant efficacy at day 15 with reduced dosing and strong tolerability, guiding a focused phase III strategy. BL1332, a potent TRPV1 antagonist, showed dramatic pain relief in a phase I-B study, supporting broader development in ocular pain. Both assets are expected to drive substantial long-term growth.
Bausch + Lomb Slides: Study result
Bausch + Lomb has posted slides in relation to its latest quarterly earnings report, which was published on August 24, 2026.
Bausch + Lomb Press release: Study result
Bausch + Lomb issued a press release on August 24, 2026, disclosing material business information to investors.
Bausch + Lomb announces Board of Directors update
Bausch + Lomb (BLCO) announced changes to its Board of Directors. At the request of Bausch Health Companies, which has held a majority ownership position in Bausch + Lomb since…
Bausch + Lomb reaffirms FY26 revenue $5.44B-$5.54B, consensus $5.49B
Bausch + Lomb (BLCO) reaffirms the full-year 2026 guidance it raised on July 29, 2026, including revenue of $5.44B-$5.54B and Adjusted EBITDA excluding Acquired IPR&D of $1.025B-$1.075B Published firs...
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the ...
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its...
Bausch + Lomb price target raised to $21 from $20 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Bausch + Lomb (BLCO) to $21 from $20 and keeps a Buy rating on the shares. The company raised…
Bausch + Lomb price target raised to $23 from $21 at UBS
UBS raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $21 and keeps a Buy rating on the shares.
Bausch + Lomb Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% revenue growth and 28% adjusted EBITDA growth, with strong performance across all segments and significant margin expansion. Guidance for full-year revenue and EBITDA was raised, supported by robust cash flow and continued deleveraging.
Bausch + Lomb Earnings release: Q2 2026
Bausch + Lomb released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Bausch + Lomb Slides: Q2 2026
Bausch + Lomb has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Bausch + Lomb Quarterly report: Q2 2026
Bausch + Lomb has published its Q2 2026 quarterly earnings report on July 29, 2026.
Bausch + Lomb Upgrades Full-Year Outlook on Strong Quarter
The eye health company raised its full-year guidance across the board, bumping its revenue target up by $20 million to a new range of $5.44 billion to $5.54 billion.